TerminatedEarly Phase 1

Brain Imaging in the Diabetes Prevention Program Outcomes Study

Stopped: Difficulty recruiting due to the COVID-19 pandemic and end of funding

United States5 participantsStarted 2019-10-01

Plain-language summary

This is a cross-sectional pilot study of Alzheimer's disease (AD) brain imaging biomarkers in Diabetes Prevention Program (DPP) outcomes study (DPPOS) participants from the New York City sites (Columbia and Einstein), comparing 10 persons originally randomized to metformin and 10 persons randomized to placebo in DPP. All study procedures will be conducted at Columbia University Irving Medical Center. Eligible participants will receive a PET scans and a brain MRI, which may be conducted in one, two, or three separate visits.

Who can participate

Age range60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Active participants in the Diabetes Prevention Program Outcomes Study (DPPOS) in New York City originally randomized to metformin or placebo * 60 years and older Exclusion Criteria: * Known dementia * Contraindications to magnetic resonance imaging (MRI) * Contraindications to radio-contrast agents.

What they're measuring

Brain Amyloid SUVR

Timeframe: Up to 1 hour post-injection

Brain Tau SUVR

Timeframe: Up to 1 hour post-injection

Trial details

NCT IDNCT03757910

SponsorJosé A. Luchsinger

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-01-31

View on ClinicalTrials.gov More Alzheimer Disease trials